Antibodies
27 April 2010
BioSante Pharmaceuticals Enters Option Agreement to its 2A/Furin Antibody Expression Technology26 April 2010
TRACON Announces Start of Phase 1/2 Trial of TRC105 Antibody Therapy for Prostate Cancer22 April 2010
Genentech Submits Supplemental Application to FDA for Herceptin in Advanced HER2-Positive Stomach Cancer22 April 2010
Amylin, Lilly and Alkermes Submit Reply to FDA Complete Response Letter for BYDUREON(TM)21 April 2010
Genmab Announces Pipeline and Technology Update21 April 2010
Seattle Genetics and Agensys, an Affiliate of Astellas, Report ASG-5ME Preclinical Data at AACR21 April 2010
AVEO Pharmaceuticals’ Selective Anti-Notch1 Monoclonal Antibody Exhibits Potent Notch1 Inhibitory Activity20 April 2010
Phase III study evaluating ocrelizumab in patients with rheumatoid arthritis meets primary endpoint20 April 2010
Seattle Genetics to Receive $9.5 Million Payment from Genentech to Extend Antibody-Drug Conjugate Collaboration19 April 2010
GlaxoSmithKline receives conditional marketing authorisation in the EU for Arzerra (ofatumumab)19 April 2010
Immunomedics Develops Novel Immunoconjugate for Targeted Delivery of siRNAs to Solid Cancers15 April 2010
Kenta Biotech Reports 100% Survival with Panobacumab in Life-Threatening Hospital-Acquired Pneumonia15 April 2010
Circadians VGX-100 Significantly Inhibits Tumour Growth in Animal Models of Human CancerNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports